Company / Cost of Revenue
Yubo International Biotech Ltd Cost of Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$4.2K
FY2025
5-year range
$822 / $185.5K
FY2021-FY2025
Trend
+409.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue changed +409% YoY in FY2025, a notable deviation from the 4-year average annual change of +129%.
Based on SEC 10-K filings.
$4,188 in FY2025 with a 5-year CAGR of -48.4%.
Improved from $185,491 to $4,188 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -56.7%
- 5-Year CAGR
- -48.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -48.4%, indicating a declining trend.
- In FY2025, cost of revenue increased 409.5% year-over-year.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -14.17 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.2K | +409.5% |
| FY2024 | $822 | -99.6% |
| FY2023 | $185.5K | +259.3% |
| FY2022 | $51.6K | -54.8% |
| FY2020 | $114.3K | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |